Market Overview

UPDATE: Ascendiant Capital Markets Reiterates On Repros Therapeutics Following Positive Topline Results

Related RPRX
Mid-Day Market Update: Crude Oil Drops Over 2%; KLA-Tencor Shares Jump On Acquisition News
Repros Receives Confirmation of Eligibility for Submission of a Centralized Marketing Authorization Application to the European Medicines Agency as a New Active Substance

In a report published Friday, Ascendiant Capital Markets analyst Keay Nakae reiterated a Buy rating on Repros Therapeutics (NASDAQ: RPRX), and raised the price target from $23.00 to $25.00.

In the report, Ascendiant Capital Markets noted, “We believe that the positive result from the ZA-305 study bodes well for a positive result from the ZA-304 study, given that the trials are identical in design. Further, we believe that positive results from these studies will also be valuable in supporting potential labeling claims for superiority of Androxal over Androgel, which would improve the commercial attractiveness of the product. Our 12 month PT is calculated using an NPV analysis.”

Repros Therapeutics closed on Thursday at $18.21.

Latest Ratings for RPRX

Oct 2015Brean CapitalDowngradesBuyHold
Oct 2015Bank of AmericaDowngradesNeutralUnderperform
Oct 2015Ladenburg ThalmannDowngradesBuyNeutral

View More Analyst Ratings for RPRX
View the Latest Analyst Ratings

Posted-In: Ascendiant Capital Markets Keay NakaeAnalyst Color Price Target Analyst Ratings


Related Articles (RPRX)

Get Benzinga's Newsletters